BioImpact Capital

MPM BioImpact is a biotechnology investment firm that builds and funds companies advancing life-saving therapies. It transforms scientific breakthroughs into impactful medicines through investment strategies spanning private and public markets. The firm leverages deep industry expertise, supporting innovative biotech ventures across all development stages, from concept to commercialization.

The firm's foundation integrates MPM Capital's three decades of venture capital experience with BioImpact's ten-year public market investing track record. This strategic convergence, guided by Chairman Ansbert Gadicke and Managing Partner Christiana Bardon, arose from the insight that a unified platform accelerates transformative therapeutic development for patients.

MPM BioImpact partners with innovative biotech enterprises focused on novel therapeutic modalities. Its vision is to catalyze creation of companies that significantly enhance patient outcomes, addressing needs from advanced RNA medicines to oncology and mental health solutions. The firm remains committed to converting scientific potential into tangible patient benefits globally.